We’re toasting the perfect end to the perfect date.

that’s living VYVIDLY™

Self-inject in ~20-30 seconds with the VYVGART Hytrulo prefilled syringe for CIDP.*
TELL ME MORE

*Please see Patient Information. Follow appropriate administration steps in the Instructions for Use. Monitor for signs and symptoms of an allergic reaction for at least 30 minutes after injection. If an allergic reaction occurs, you should seek medical attention.

We want to hear your CIDP story! Call 1-844-674-3504 for more information on the CIDP Patient Ambassador Program.

A different approach to CIDP

VYVGART Hytrulo works differently than other CIDP treatments, including IVIg, SCIg, PLEX, and steroids.

Megaphone

VYVGART Hytrulo is the first major innovation in CIDP treatment in over 30 years.†

Syringe

You and/or your caregiver will receive in-person training at home or in your doctor’s office until you’re ready to inject on your own with the prefilled syringe. You’ll also get a demonstration kit to help you practice.

Droplet crossed out

The first and only plasma-free treatment approved by the FDA for CIDP.

†VYVGART Hytrulo contains efgartigimod alfa and hyaluronidase, and is specifically designed to attach to FcRn receptors.
FcRn=neonatal Fc receptor; IVIg=intravenous immunoglobulin; PLEX=plasma exchange; SCIg=subcutaneous immunoglobulin.

About the VYVGART Hytrulo clinical study

document with magnifying glass

Learn about the effectiveness and safety of VYVGART Hytrulo—established in the largest clinical study in CIDP history

reduced risk

See how the VYVGART Hytrulo study measured the reduced risk of arm and leg symptoms getting worse

99%

of eligible patients chose to be part of an extended safety study and receive VYVGART Hytrulo (226 out of 228 patients)

Taking the Lead
Taking the Lead

Watch the virtual event: Wednesday, February 4,
at 2 PM & 7 PM ET

Hear firsthand from people living with CIDP, a neurologist, and other medical experts about how self-injection with the VYVGART Hytrulo prefilled syringe has helped the CIDP community fit treatment into their lives.

SAVE MY SPOT

Real stories with VYVGART Hytrulo

Want to hear from people living with CIDP, in their own words? Read their personal experiences and watch them come to life. Discover how they’ve managed their CIDP with VYVGART Hytrulo—and imagine what it could do for you.

SEE THEIR STORIES

Connect with a mentor who’s treating their CIDP with VYVGART Hytrulo

Talk one-on-one with a mentor who can share personal experience with VYVGART Hytrulo and offer a safe space to discuss your CIDP journey. Whether by phone or video call, you choose how to connect.

ENROLL NOW

Share your CIDP experience with your neurologist

The CIDP Doctor Discussion Guide can help you take note of your CIDP symptoms and abilities. Providing a better understanding of your daily life with CIDP may help your doctor determine if VYVGART Hytrulo is right for you.

GET YOUR GUIDE

Share your story

Your story is special because it is yours to tell. Sign up for the CIDP Patient Ambassador Program so you can make your mark on the CIDP community by sharing your personal experience living with or caring for someone with CIDP.

Make a difference and join us to inspire others. Learn more about the CIDP Patient Ambassador Program by calling us at 1-844-674-3504 or email amalia@mypatientstory.com.

Kristen headshot Kristen headshot Kristen headshot

“I’m really seeing meaningful gains! Having the time to make plans might be the biggest gain of all.”

Kristen, taking VYVGART Hytrulo for CIDP

Kristen is a paid spokesperson.

READ HER STORY
My PRODUCT Y Path

Pay as little as $0 for VYVGART Hytrulo and related administration costs‡

My VYVGART Path is a program that provides personalized support for every step of your VYVGART Hytrulo journey, including help understanding potential financial assistance. Once enrolled, a dedicated Nurse Case Manager can share education and resources on everything from insurance to self‑injection with the VYVGART Hytrulo prefilled syringe.

LEARN MORE

‡Eligible commercially insured patients may pay as little as $0 for VYVGART Hytrulo and may receive a maximum benefit of $25,000 per calendar year for their eligible out-of-pocket costs for the drug and drug administration. Persons residing in MA and RI are not eligible for financial assistance related to administration costs. Please see full Terms and Conditions.

95%

of people with CIDP were satisfied with the support they received through My VYVGART Path§

§Based on an online survey from December 2024 of 81 respondents enrolled in My VYVGART Path.

Have questions? Call 1-833-VYV-CIDP (1-833-898-2437) to speak with an educator about CIDP, how VYVGART Hytrulo works, study results, cost and coverage, and more.

Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge
  • Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • hives
    • trouble breathing
    • low blood pressure
    • fainting
  • Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

It is not known if VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.

Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge
  • Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • hives
    • trouble breathing
    • low blood pressure
    • fainting
  • Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

It is not known if VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.

Questions? Call 1-833-VYV-CIDP
(1-833-898-2437)

This site is intended for patients and caregivers.

Disclaimer | Privacy Policy | Contact Us |

Patient and Prescribing Information
VYVGART Hytrulo Patient Information VYVGART Hytrulo Prescribing Information VYVGART Hytrulo Prefilled Syringe Instructions for Use

VYVGART and VYVGART Hytrulo are registered trademarks of argenx.

LIVE VYVIDLY and THAT’S LIVING VYVIDLY are trademarks of argenx.

For U.S. audiences only.

©2025 argenx 

US-VYV_HYT-24-00518 V4 11/2025

argenx logo